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LATE-BREAKING CLINICAL TRIALS
Results From Late-Breaking Clinical Trials Sessions at ACC ’98
EDWIN L. ALDERMAN, MD, FACC
Stanford, California
Late-Breaking Clinical Trials I
Amiodarone Reduces CABG Hospitalization
(ARCH)
THOMAS GUARNIERI, MD, FACC
GREATER BALTIMORE MEDICAL CENTER, BALTIMORE, MARYLAND
The authors addressed the hypothesis that intravenous amio-
darone given immediately postoperatively will reduce the
incidence of atrial fibrillation, therefore reducing the length of
stay. They selected a protocol that was amenable to postoper-
ative administration because ;60% of patients in their hospi-
tal undergo urgent bypass procedures (i.e., they arrive in need
of coronary artery bypass graft surgery).
All subjects in this trial received 2 g of intravenous amio-
darone, given over 2 days without a loading dose. Patients were
randomized to receive placebo (n 5 142) or amiodarone (n 5
158). Sixty-seven patients in the placebo group (;47%) devel-
oped atrial fibrillation. With amiodarone, the incidence was
reduced to 35%, a statistically significant difference. Length of
stay was shortened by 1 day, an insignificant result.
A previously published study (Daoud et al. [1]) that found
a large benefit for amiodarone identified patients ;1 week
before operation. Each patient was given ;600 mg for 7 days
and then 200 mg for 7 days. The results of these studies suggest
that success depends on how soon a patient can be treated and
on the dose of amiodarone.
Commentary. The prevalence of atrial fibrillation after
cardiac surgery is such that measures to reduce length of stay
are worthwhile. Amiodarone reduced the incidence of atrial
fibrillation by a modest but significant degree in this study. The
absence of a loading dose and the small study size may have
worked against demonstrating a cost benefit. Future studies
ideally should include a beta-adrenergic blocking agent and
sotolol in the comparisons.
Cardiac Arrest Study Hamburg (CASH)
KARL H. KUCK, MD, FACC
ST. GEORGE HOSPITAL, HAMBURG, GERMANY
This study was designed as an open, randomized, multicenter
trial to assess the efficacy of the implantable cardioverter-
defibrillator (ICD) compared with antiarrhythmic drugs in
survivors of sudden cardiac death.
The final analysis of the trial was performed in December
1997 after a 2-year follow-up was completed for all 346
patients. Patients were randomized to receive an ICD (n 5 99)
or amiodarone (300 mg/day [n 5 92]) or metoprolol
(100 mg/day [n 5 97]) treatment. A propafarone arm had been
stopped in 1993. During follow-up, the total mortality rate for
the ICD treatment arm was 12.1% compared with 19.6% for
the amiodarone and metoprolol arms. The reduction in overall
mortality in the ICD group was 37%, with a one-sided p value
of 0.047. There was no difference between patients treated with
amiodarone and those treated with metoprolol.
There was a significant decrease in sudden cardiac death in
ICD-treated patients compared with those who were medically
managed (2% vs. 11%, p , 0.037). The absolute number of
sudden cardiac deaths was 11 each in the amiodarone and
metoprolol arms versus only 2 in the ICD arm.
Commentary. The group size for the comparison of ICDs
with amiodarone is relatively small, and the lengthy recruit-
ment raises questions about patient heterogeneity. However,
the significant benefits of ICDs (and transvenous systems in
particular) for sudden death survivors confirm the previously
reported results from the Antiarrhythmics Versus Implantable
Defibrillators (AVID) trial.
Canadian Implantable Defibrillator Study (CIDS)
STUART J. CONNOLLY, MD, FACC
MCMASTER UNIVERSITY, HAMILTON, ONTARIO, CANADA
The CIDS hypothesis was that the implantable cardioverter-
defibrillator (ICD) would reduce the risk of death in patients
who had had either a cardiac arrest or an episode of sustained,
symptomatic ventricular tachycardia compared with no ICD
therapy (transvenous in 89% of ICD recipients).
The investigators enrolled 659 patients. After 3 years of
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follow-up, there was a 19.6% reduction in all-cause mortality in
patients randomized to receive the ICD (25% for ICD vs. 30%
for amiodarone, p 5 0.07). Among patients randomized to
receive the ICD, inappropriate shocks continued to occur over
time, reaching almost 30% by 5 years, whereas appropriate
shocks reached 60% by 5 years.
In the amiodarone group, 22% of patients received subse-
quent ICDs. In the ICD group, more patients at all times were
taking beta-adrenergic blocking agents or sotalol than were
amiodarone-assigned patients. For example, at 3 years, ;60%
of ICD-treated patients were receiving either a beta-blocker or
sotalol compared with ;25% of amiodarone-treated patients.
Commentary. It is somewhat surprising that ICDs failed to
demonstrate a significant survival benefit over amiodarone in
this adequately powered study of 659 patients who were sudden
death survivors or had life-threatening ventricular arrythmias.
There was a distinct trend toward benefit; however, use of
antiarrhythmic drugs by ICD-treated patients, crossover to ICDs
in medically assigned patients and concomitant beta-blocker use
probably muted survival differences between the groups.
Randomized Evaluation of Strategies for Left
Ventricular Dysfunction (RESOLVED)
SALIM YUSUF, MD, PHD, FACC
HAMILTON GENERAL HOSPITAL, HAMILTON, ONTARIO, CANADA
JEAN-LUCIEN ROULEAU, MD, FACC
MONTREAL HEART INSTITUTE, MONTREAL, QUEBEC, CANADA
The first part of the RESOLVED study addressed a compar-
ison of the angiotensin II (AII) receptor antagonist candesar-
tan versus enalapril versus the combination of both. Random-
ized patients (n 5 769) had heart failure and a left ventricular
ejection fraction (LVEF) ,40% and were in New York Heart
Association functional class II or higher.
At 2, 18 and 43 weeks, there was no reduction in blood
pressure in the candesartan- and enalapril-only groups. How-
ever, combination therapy did cause a 5-mm decrease in
systolic blood pressure that was significantly different from
both enalapril and candesartan alone.
On the 6-min walk tests at 18 weeks, there was a small
improvement with enalapril and a somewhat smaller improve-
ment with candesartan compared with their combination,
which was nominally significant. At 43 weeks, these differences
narrowed, so that the differences between the three groups
were no longer significant.
The data on ventricular function revealed very little change
at 17 weeks. However, at 43 weeks there was a significant
improvement in ventricular dilation for the drug combination
compared with enalapril or candesartan alone. This improve-
ment was more marked in patients at the medium dose of the
combination, a group in which LVEF improved more than with
enalapril alone.
After 6 months, 450 of the patients in the angiotensin-
converting enzyme (ACE) inhibitor versus AII blocker trial
were randomized to receive a long-acting preparation of
metoprolol or placebo. At 24 weeks, there were no significant
differences in the 6-min walk, functional class or quality of life.
Metoprolol reduced activation of the angiotensin system and
increased atriuretic and brain natriuretic peptide levels. Meto-
prolol improved LVEF and prevented the ventricular dilation
noted in the placebo group.
The number of patients and 6-month duration of follow-up
were too limited to provide meaningful results on clinical end
points. The effects of ACE inhibitor and angiotensin blocker
therapy were similar to those of combination therapy, showing
best improvement in LVEF. There was a trend toward im-
proved survival with metoprolol.
The overall conclusion of this pilot study was that more
comprehensive neurohormonal modulation is a promising
direction for future research, reflecting benefits in ventricular
function and remodeling.
Commentary. This complex study did not resolve the ques-
tion of the relative advantages of ACE inhibitor over angio-
tensin blocker for treatment of heart failure. RESOLVED was
a short-term study not sized to assess major clinical end points.
Both the ACE inhibitor and the AII blocker had similar bio-
chemical and physiologic effects, and the combination exerted the
greatest benefit. It would seem that an adequate dose of one or
the other blocker is likely to be most cost-effective.
Assessment of Treatment With Lisinopril and
Survival (ATLAS)
MILTON PACKER, MD, FACC
COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SURGEONS,
NEW YORK, NEW YORK
On average, doses of angiotensin-converting enzyme (ACE)
inhibitors used in clinical trials are four to six times larger than
doses used in clinical practice, but it is unclear whether the low
doses of ACE inhibitors used in clinical practice are as effective
as those used in clinical trials.
In the ATLAS trial, 3,164 patients in New York Heart
Association functional classes II to IV and under treatment
with digoxin and a diuretic drug were enrolled in 19 countries.
After a run-in phase, 1,568 patients were randomized to
receive 2.5 to 5 mg/day of lisinopril, and 1,596 were random-
ized to receive 32.5 to 35 mg/day. The groups were well
matched with respect to all baseline characteristics.
After a median follow-up period of 46 months, for all-cause
mortality there were 717 deaths in the low dose group and 666
in the high dose group. These figures represent an 8% lower
risk of death in the high dose group (p 5 0.128). Cardiovas-
cular mortality decreased from 40.2% in the low dose group to
37.2% (p 5 0.073). For the secondary end point of death or
hospital admission for any reason, there were 1,339 events in
the low dose group and 1,251 events in the high dose group
(83.9% vs. 79.8%, p 5 0.002). Hospital admissions for conges-
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tive heart failure were reduced by 24% in the high dose group
(p 5 0.003).
These results were almost precisely half of the risk reduc-
tions that were observed in the Studies of Left Ventricular
Dysfunction (SOLVD) treatment trial, which compared high
doses of ACE inhibitors with placebo. Therefore, although it is
necessary to be very careful about comparing treatment effects
across studies, this comparison suggests that low doses produce
;50% of the treatment effect seen with high doses. It also
suggests that physicians have as much reason to increase the
dose of an ACE inhibitor from low to high dose as they have
in starting an ACE inhibitor and maintaining it at a low dose.
Commentary. Clinical trials used for Food and Drug Ad-
ministration drug approvals are usually designed with doses
that are selected to maximize benefit but are just short of
causing adverse reactions. This comparison of high versus low
dose ACE inhibitor (lisinopril) to some extent compares
extremes of the dose spectrum. This study, although originally
sized to show a mortality difference, failed to do so. However,
the major differences were in the secondary end points, which
showed that a high dose ACE inhibitor significantly reduced
hospital admissions for heart failure. Given the prevalence and
cost of these events, such reductions are no small matter.
Late-Breaking Clinical Trials II:
Interventions for Atherosclerosis
Direct Antithrombin–Argatroban in Acute
Myocardial Infarction (ARGAMI-2)
ELIESER KAPLINSKY, MD, FACC
HEART INSTITUTE, SHEBA MEDICAL CENTER,
TEL-HASHOMER, ISRAEL
ARGAMI-2 was a double-blind, randomized study of two
doses of the direct thrombin inhibitor argatroban versus hep-
arin as adjuvant therapy to tissue-type plasminogen activator
or streptokinase in acute myocardial infarction. The trial was
originally designed to enroll 1,200 patients; however, after
enrolling 600 patients, the data and safety monitoring commit-
tee terminated the low dose argatroban group because of lack
of efficacy.
At the end of the study, therefore, 1,001 patients were
randomized to receive either high dose argatroban or heparin.
At 30 days, there were two major cases of bleeding in the
argatroban group versus six in the heparin group. There were
no intracerebral hemorrhages in the argatroban group versus
two in the heparin group. The rate of minor bleeding was 5.9%
for argatroban and 8.3% for heparin, but this difference was
not significant.
Clinical end points were total mortality, recurrent myocar-
dial infarction, pump failure, interventions for ischemia and
ischemic stroke. There were no differences in either the
combined incidence of these end points or any of the individual
components of the end point.
Commentary. Because of the relatively short action dura-
tion of thrombolytic agents, the standard adjunctive therapy to
prevent rethrombosis has been heparin. Direct thrombin in-
hibitors may be more beneficial in preventing recurrent throm-
bus; however, this trial (and a previously reported study) failed
to show any benefit (or harm) from use of argatroban, a
peptide thrombin inhibitor, compared with heparin. From an
economic perspective, it is just as well that another expensive
adjunctive therapy need not be used in the management of
patients with an acute myocardial infarction.
Multicenter, Randomized Trial of Abciximab in
Stenting and Comparison With Abciximab Plus
Balloon (EPILOG Stent)
ERIC J. TOPOL, MD, FACC
CLEVELAND CLINIC FOUNDATION, CLEVELAND, OHIO
In this trial, 2,399 patients undergoing percutaneous coronary
interventions with lesions suitable for stenting were random-
ized at 63 sites in the United States and Canada to one of three
arms: stent plus placebo, stent plus abciximab; or percutaneous
transluminal coronary angioplasty (PTCA) plus abciximab.
At 30 days, the rate of death, myocardial infarction or
revascularization for ischemia was 10.8% in the stent plus
placebo group, 5.3% in the stent plus abciximab group and
6.9% in the PTCA plus abciximab group. Most of the differ-
ence was caused by a reduction in the rate of myocardial
infarction, which dropped from 9.6% in the stent monotherapy
group to 4.5% in the stent plus abciximab group.
The combination of stents and abciximab outperformed the
other groups in a wide range of subgroups. One exception was
women, in whom the combination of abciximab and PTCA
produced the best result. Only relatively large, 3-mm stents
were available for the trial, and some women may have
benefited from smaller stents.
Commentary. These results along with results of the pre-
vious EPILOG trial confirm the benefit of the glycoprotein
IIa/IIIb platelet receptor inhibitor abciximab for prevention of
acute complications associated with angioplasty with or with-
out stenting. Does abciximab need to be an adjunct to every
percutaneous intervention, barring contraindications? Although
this study reported that most patient groups benefited, the
relatively high event rate for elective stenting in the heparin
control group suggests that it would be preferable to define the
clinical and angiographic features of those patients at highest risk
for thrombosis who would be most likely to benefit.
Plasminogen Activator and Angioplasty
Compatibility Trial (PACT)
ALLAN M. ROSS, MD, FACC
GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER,
WASHINGTON, D.C.
In this trial, 606 patients with an acute myocardial infarction
within 6 h of symptom onset were randomized to receive either
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a 50-mg bolus of tissue-type plasminogen activator (t-PA) or
placebo. Patients then underwent immediate catheterization.
If the vessel was still closed (Thrombolysis in Myocardial
Infarction [TIMI] flow grade 0 or 1) or had incomplete flow
(TIMI flow grade 2), then immediate angioplasty was per-
formed. However, in patients with normal flow (TIMI flow
grade 3), angioplasty was not performed, and the patients
received a second bolus of either t-PA or placebo.
The initial angiogram revealed that 14.8% of patients in the
placebo group had TIMI grade 3 flow, and an additional 19%
had TIMI grade 2 flow. In the t-PA group, 32.8% had TIMI
grade 3 flow, and 27.7% had TIMI grade 2 flow. The success
rate of angioplasty, when required, in restoring TIMI grade 2
or 3 flow was similar in both groups, ;95%. The rate of TIMI
grade 3 flow after PTCA was ;78%.
There were no differences in adverse events between the
two groups. One intracranial hemorrhage occurred in each
group.
Among patients who had TIMI grade 3 flow on first
catheterization, the left ventricular ejection fraction was 62%.
The left ventricular ejection fraction in patients who achieved
TIMI grade 3 flow only after angioplasty was 58% and was
55% among those who never achieved TIMI grade 3 flow (both
significantly lower than those with TIMI grade 3 flow on first
catheterization).
Commentary. When angioplasty at appropriately equipped
facilities became an option for treatment of acute myocardial
infarction, there was reluctance to give a thrombolytic agent to
patients undergoing procedures because of increased compli-
cation rates. However, this study administered a lower total
dose of t-PA as a single bolus (50 mg) without increasing the
number of adverse events. The greater proportion of patients
with TIMI grade 2 and 3 flow on initial culprit artery visual-
ization suggests the potential for increased myocardial salvage.
Considering the delays from myocardial infarction diagnosis to
coronary artery recanalization, long-term clinical benefit may
be associated with this approach. However, a larger, long-term
clinical study would be required to assess benefit and to ensure
absence of increased bleeding risk.
Primary Angioplasty in Myocardial Infarction Trial
(Stent-PAMI)
CINDY L. GRINES, MD, FACC
WILLIAM BEAUMONT HOSPITAL, ROYAL OAK, MICHIGAN
In this trial, 900 patients with an acute myocardial infarction in
North and South America, Europe, the Middle East and Japan
were randomized to either receive the heparin-coated Palmaz-
Schatz stent or to undergo primary percutaneous transluminal
coronary angioplasty (PTCA). In the PTCA arm, there were 67
crossovers to the stent arm, for a crossover rate of ;15.1%. All
but 2.6% of patients randomized to the stent arm actually
received the heparin-coated stent.
Angiographic data at 1 month from the core laboratory
were available for 80% of patients. The residual rate of
stenosis was 19% in the stent group versus 29% in the PTCA
group. There was a 0.4-mm advantage for the stent with regard
to minimal lumen diameter after the procedure (p 5 0.001).
The angioplasty success rate, defined as TIMI grade 2 and 3
flow, was 99.2% in the stent group and 97.7% in the PTCA
group. However, the TIMI grade 3 flow rate was 88.6% in the
stent group versus 92.3% in the PTCA group.
There were no significant differences in clinical events at 1
month. The 6-month data will reveal whether the stent reduced
the rate of target vessel revascularization. There was a trend
toward a shorter hospital stay in the stent group, with the
difference in the subgroup of patients treated in the United
States reaching statistical significance.
Commentary. The Stent-PAMI trial represents a selected
cohort of patients with an acute myocardial infarction who
were candidates for both balloon and stent procedures and had
a subsequent 1-month mortality rate of 1.8% (PTCA group)
versus 3.5% (stent group). Despite the expected larger initial
lumen gain after stenting than after PTCA, the clinical results
at 1 month showed minimal differences between groups both
during the hospital stay and after 1 month, verifying the safety
of stenting during the acute phase of infarction. The 6-month
results will be of more interest. It should be noted that this
study does not address the issue of whether acute intervention
has advantages over thrombolytic drug therapy, the use of
which was an exclusion from entry into this trial.
Total Occlusion Study of Canada (TOSCA)
CHRISTOPHER E. BULLER, MD, FACC
VANCOUVER GENERAL HOSPITAL, VANCOUVER,
BRITISH COLUMBIA, CANADA
The TOSCA trial was a randomized study of primary stenting
using the heparin-coated Palmaz-Schatz stent versus balloon
angioplasty in 410 patients with nonacute total coronary occlu-
sions. The primary end point of the trial was failure of
sustained patency at or before 6 months. The rate of crossover
during the initial procedure from balloon to stent was 10% and
4% from stent to balloon. Target lesions were complex, with an
average lesion length of 35 mm, an average of two stents per
stented lesion and frequent coexistence of lesion-related
thrombus or calcification.
At 6 months, there were more completely patent arteries in
the stent arm than in the percutaneous transluminal coronary
angioplasty (PTCA) arm. The rate of Thrombolysis in Myo-
cardial Infarction [TIMI] grade 0, 1 or 2 flow (failed patency)
was 19.5% in the PTCA group versus 10.9% in the stent group.
This difference represents an absolute reduction of 8.6% and a
relative reduction of 44% with stents.
Initial postprocedural minimal lumen diameters (MLDs)
were larger in the stent group than in the PTCA group (2.45 vs.
1.96 mm), as were the final MLDs (1.48 vs. 1.23 mm). The
binary angiographic restenosis rates were high at 70% in the
PTCA arm and 56% in the stent arm, reflecting both the lesion
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complexity and the quantitative coronary angiographic analysis
using proximal reference segments exclusively.
In contrast, target vessel revascularization after the initial
procedure was required in 13.9% of PTCA-treated patients
versus 7.4% of stent-treated patients, a statistically significant
47% relative reduction. These revascularization rates repre-
sent clinically driven procedures before protocol angiography
only. There were no other significant differences in clinical end
points.
Commentary. It is well known that interventions for total
occlusions still have a high incidence of both early and late
reocclusion. It is logical and experientially evident that a larger
postprocedural lumen might decrease reocclusions. This size-
able study provides objective data that stenting, which yielded
a postprocedural lumen of 2.45 mm, results in an impressive
89% TIMI grade 3 flow at 6 months.
Late-Breaking Clinical Trials III: New
Observations From Recent Clinical Trials
Azithromycin in Coronary Artery Disease
Elimination of Myocardial Infection With
Chlamydia (ACADEMIC)
JEFFREY L. ANDERSON, MD, FACC,
JOSEPH B. MUHLESTEIN, MD, FACC
LDS HOSPITAL, SALT LAKE CITY, UTAH
The ACADEMIC study was undertaken to test whether
azithromycin would reduce systemic markers of inflammation,
antibody titers to Chlamydia pneumoniae and vascular events
in patients with symptomatic coronary artery disease (CAD).
The study was designed as a double-blind, randomized, sec-
ondary prevention trial in patients with documented CAD and
elevated IgG titers to C. pneumoniae. Patients were random-
ized to receive azithromycin or placebo for 3 months.
Three hundred two patients with CAD and positive sero-
logic titers were randomized. No significant change in
C-reactive protein (CRP) occurred in either group at 3
months; however, a statistically significant rise in CRP was
observed in the placebo group at 6 months but not in the group
receiving azithromycin therapy, although at 6 months an
overall difference was suggested.
At 3 months, both treatment groups showed a slight reduc-
tion in the level of activity of interleukin (IL)-6. However, by 6
months IL-6 had rebounded to levels higher than those at
baseline in the placebo group, an effect that was significantly
blunted in patients receiving azithromycin. No significant
differences in other inflammatory cytokines, IL-1 or tumor
necrosis factor were observed. In addition, there were no
significant differences in a combined analysis of all four
markers of inflammation at 3 months.
The primary clinical end point of the study is the 2-year
outcome. Therefore, both patients and investigators remain
blinded to treatment assignment. An interim analysis at 6
months found only a 5% rate of major cardiovascular end
points (16 events), thus far evenly distributed between the two
treatment groups.
Commentary. The initial British (Gupta et al.) and Argen-
tine trial results suggested that antibiotic therapy might benefit
patients with symptomatic coronary disease, raising the possi-
bility that Chlamydia infection may be promoting plaque
growth. However, at 6 months in the ACADEMIC study there
was no difference in clinical events between treatment groups,
although events were few. There is evidence of only a modest
anti-inflammatory response after azithromycin in these pa-
tients, all of whom had positive serology titers at study entry.
This trial does not exclude the possibility of a contributory role
of infection as a factor in the pathogenesis of the atheroscle-
rosis, but larger and longer trials will be required.
Preliminary Results of Long-Term Follow-Up of
the Post-Coronary Artery Bypass Graft Trial
(Post-CABG)
GENELL L. KNATTERUD, PHD
MARYLAND MEDICAL RESEARCH INSTITUTE,
BALTIMORE, MARYLAND
YVES ROSENBERG, MD, MPH
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE,
BETHESDA, MARYLAND
The Post-CABG trial was a multicenter, double-blind, ran-
domized trial that included 1,351 patients who had undergone
coronary artery bypass graft surgery 1 to 11 years previously
and had a baseline low density lipoprotein (LDL) cholesterol
level between 130 and 175 mg/dl. The Post-CABG trial used a
2 3 2 factorial design, with patients randomly assigned to
either aggressive or moderate LDL cholesterol lowering, with
lovastatin and cholestyramine added as necessary in each
group. Patients were also randomized to receive either low
dose warfarin (international normalized ratio ,2) or placebo.
The follow-up period during the trial averaged 4.3 years,
and the extended follow-up added another 3 years. At the end
of the trial, patients were advised to take aspirin and
cholesterol-lowering medications to keep their LDL choles-
terol ,100 mg/dl, but limited information is available on the
treatment actually received. There were no differences be-
tween the aggressive and moderate lipid-lowering groups in
the occurrence of death or myocardial infarction during the
trial or during the period of extended follow-up. During the
course of the trial, there were fewer revascularization proce-
dures in the group assigned to aggressive lipid-lowering ther-
apy than in the moderate group, but this difference was not
significant. However, with the addition of another 3 years of
follow-up, the difference in the number of revascularization
procedures between the groups was significant, yielding a 29%
reduction in the aggressive lipid-lowering group (p 5 0.001).
During the trial, there was no difference between the
warfarin and placebo groups in the occurrence of death or
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myocardial infarction; however, a significant 31% difference
(p 5 0.001) in favor of warfarin emerged during the period of
extended follow-up. No differences between the warfarin and
placebo groups in the rate of revascularization were observed
either during the trial or during the extended follow-up.
Commentary. The Post-CABG study was primarily an an-
giographic trial that showed no benefit of warfarin at the time
of initial trial close-out. However, with an additional 3 years of
follow-up, there was a perplexing observation of improved
survival, despite the fact that patients were no longer taking
the drug. With lengthened follow-up, patients who had in
earlier years received study-directed, lipid-lowering medica-
tion subsequently required fewer revascularization procedures.
Delayed benefit of risk reduction has been noted in previous
trials of niacin, a result that is consistent with the angiographic
benefit that had already been shown for lipid lowering.
Angioplasty Compared to Medicine (ACME):
Five-Year Clinical and Economic Outcomes
PAMELA M. HARTIGAN, PHD, MPH
WEST HAVEN VA MEDICAL CENTER, WEST HAVEN, CONNECTICUT
The ACME study was designed to compare percutaneous
transluminal coronary angioplasty (PTCA) and medical ther-
apy in patients with single-vessel coronary disease. Although
both treatments were found to be effective, the PTCA-treated
patients had a significantly longer exercise duration, and
significantly more of them were angina free at the time of the
6-month, previously published, evaluation. However, more of
these patients did require bypass surgery.
Of 328 patients, 166 were randomized to PTCA and 162
were randomized to medical therapy. At 5 years, 67% of
PTCA-treated patients were angina free compared with 55%
of medically treated patients. Furthermore, at 5 years, almost
one-third of PTCA-treated patients were free of antianginal
drugs compared with only 17% of medically treated patients.
Both patient groups improved significantly from baseline on
a quality of life instrument, but the PTCA group did much
better at the 6-month evaluation than did the medical group.
The median results for the PTCA group remained above the
medical group at each time point after 6 months, without
significant variations over time.
At the beginning of the study, the initial cost of the PTCA
procedure resulted in a difference of almost $9,000. This
expense increased over the first 6 months to ;$11,500. Over
the subsequent 4.5 years, the difference gradually decreased
such that by 5 years, it had been reduced to $7,500.
Commentary. ACME is one of the few trials to pit PTCA
against medical treatment for patients with single-vessel coro-
nary disease, who because of excellent longevity are unsuited
for a survival end point study. Relief of ischemic symptoms was
measurably better with PTCA but at considerable cost for the
initial and restenosis procedures. However, after 5 years of
follow-up a $1,500 incremental cost per year yielded clear gains
in functional status for ;15% of patients. Perhaps it is time for
a new trial using current device technology and contemporary
risk reduction strategies to better define the trade-offs between
interventional and medical treatment strategies for patients
not requiring surgical revascularization.
Prevalence of Valvular Abnormalities in Patients
Exposed to Dexfenfluramine: Results of a
Randomized, Placebo-Controlled Trial
NEIL J. WEISSMAN, MD, FACC
GEORGETOWN UNIVERSITY MEDICAL CENTER, WASHINGTON, D.C.
A total of 1,212 patients had been randomized in a prospective
trial to receive dexfenfluramine (Redux), sustained-released
dexfenfluramine, or placebo for the treatment of obesity, of
whom 1,072 had an echocardiographic examination a median
of 2.5 months after starting treatment. According to the Food
and Drug Administration (FDA), significant mitral regurgi-
tation is considered to be present if it is of moderate or
greater severity and significant aortic regurgitation is
present if it is mild or greater in severity. The patients in the
study were predominantly female, middle aged, white and
obese.
The prevalence of mild or worse aortic regurgitation in
the dexfenfluramine-treated group, the sustained-released
dexfenfluramine-treated group and the placebo group was
5.0%, 5.8% and 3.6%, respectively. The three-group difference
was not significant (p 5 0.43). The prevalence of moderate or
worse mitral regurgitation was 1.7%, 1.8% and 1.2% in the
same three treatment groups (p 5 0.86). The prevalence of any
significant regurgitation in the same three groups was 6.5%,
7.3% and 4.5% (p 5 0.30).
There were no significant differences among groups for
tricuspid or pulmonary regurgitation, estimated pulmonary
artery pressure or serious events. Abnormality of mitral leaflet
mobility was somewhat more prevalent in the dexfenfluramine-
treated groups (p 5 0.045).
This study suggests that the prevalence of significant regur-
gitation for dexfenfluramine is much lower than the previously
reported 32.8%. Therefore, these results should be reassuring
to the majority of patients who have taken dexfenfluramine for
2 to 3 months.
Commentary. When dexfenfluramine was withdrawn from
the market, some estimates of valvular and pulmonary vascular
abnormalities exceeded 20%. The relatively benign results of
this serendipitous echocardiographic study can be applied only
to those patients taking dexfenfluramine for ,3 months and
without other drugs. The report by Connolly et al. (2) in The
New England Journal of Medicine described 24 women who took
fenfluramine–phentermine combinations for a mean 12.3
months at the time of their substantially abnormal echocardio-
graphic examinations. The real prevalence of valvular and
pulmonary abnormalities for patients taking drug combina-
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tions remains unknown in the absence of thorough epidemio-
logic surveys.
Update on the Clinical and Health Economic
Outcomes From the Long-Term Intervention With
Pravastatin in Ischemic Disease (LIPID) Study
R. JOHN SIMES, MD
UNIVERSITY OF SYDNEY, SYDNEY, AUSTRALIA
Patients between the ages of 31 and 75 years with a previous
acute myocardial infarction or unstable angina were random-
ized to receive either pravastatin or placebo (n 5 9,014).
Women comprised 17% of the study population. Patients were
followed up for an average of 6.1 years.
Pravastatin caused an 18% reduction in total cholesterol, a
25% reduction in low density lipoprotein cholesterol, a 6%
increase in high density lipoprotein cholesterol and an 11%
decrease in triglycerides.
Total mortality was reduced by 23% or, in absolute terms,
30 deaths were prevented for every 1,000 patients treated for 6
years. Cardiac mortality, the primary outcome of the study, was
reduced by 23%, for an absolute reduction of 19 coronary
deaths avoided for every 1,000 patients treated over 6 years.
Pravastatin reduced the overall number of hospital admis-
sions, from 12,794 in the placebo group to 11,709 in the
treatment group. The length of the hospital stays were also
reduced by almost half a day in the pravastatin group. A
preliminary cost analysis in this secondary prevention trial
found that the cost per year of life saved was in the range of
$8,000 to $12,000.
Commentary. This previously reported secondary preven-
tion trial of pravastatin is sufficiently large that the benefits on
survival and event rates were confirmed for multiple patient
subsets. The cost per year of life saved is well below the renal
dialysis benchmark. The results of the American College of
Cardiology Evaluation of Prevention Therapies (ACCEPT)
and Lipid Treatment Assessment Project (L-TAP) studies
(also presented at ACC ’98) suggested that physicians are not
applying existing guidelines to the extent that would achieve
the results observed in this study.
Update on the Clinical and Health Economic
Outcomes From the Air Force/Texas Coronary
Atherosclerosis Prevention Study
(AFCAPS/TEXCAPS)
ANTONIO GOTTO, JR., MD, DPHIL
CORNELL UNIVERSITY MEDICAL COLLEGE, NEW YORK, NEW YORK
AFCAPS/TEXCAPS was a double-blind, randomized,
placebo-controlled, primary prevention study to determine
whether treatment with lovastatin would reduce the combined
incidence of fatal or nonfatal myocardial infarction, unstable
angina or sudden cardiac death. The trial enrolled 5,608 men
and 997 women with qualifying high density lipoprotein (HDL)
cholesterol ,50 mg/dl and a total HDL cholesterol ratio .5.
The treatment included the American Heart Association Step
I diet. Lovastatin was titrated to bring low density lipoprotein
(LDL) cholesterol to ,110 mg/dl versus placebo.
The study was stopped in July 1997. The maximal follow-up
period was 7.2 years (overall median was 5.1). The primary end
point was reached in 183 placebo-treated patients and 116
lovastatin-treated patients. The first acute major coronary
event was reduced by 37% (p 5 0.00008) during the 5-year
period by lovastatin.
An analysis of resource utilization found a significant 29%
reduction in the cumulative number of hospital admissions and
procedures for cardiovascular disease in the lovastatin group.
Lovastatin reduced the frequency of bypass surgery by 18%
and coronary angioplasty by 37%. Diagnostic procedures were
also significantly reduced: electrocardiography by 21%, cathe-
terization by 28%, echocardiography by 24% and thallium
stress testing by 11%.
The average cost per patient for hospital admission and
diagnostic and therapeutic procedures was reduced from
$2,100 to ;$1,500, a 28% reduction. The total cost of the drug
for the trial duration was $4,700.
Commentary. This primary prevention trial potentially ex-
tends the indications for lipid lowering beyond the current
National Cholesterol Education Program guidelines, which
specify two major risk factors and LDL cholesterol $130
mg/dl. Given a total 5-year difference of 67 acute coronary
events in 6,605 patients (1% of patients), one must be cautious
before applying the entry guidelines of this trial to the general
public. Relevant factors in the outcome of this study may have
been the protocol-directed lovastatin titration to LDL choles-
terol #110 mg/dl and a somewhat higher prevalence of low
HDL and positive family history in the study patients than in
the general population. The per-patient total 5-year drug cost
of $4,700 yielded a $587 reduction in health care costs along
with avoidance of life-threatening events. Further analyses are
needed to define patient subgroups that would benefit the
most.
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